dopamine precursor

Assets acting on this target.

Class
Levodopa-based dopamine replacement

Levodopa is the metabolic precursor of dopamine, the neurotransmitter whose progressive loss from neurons connecting the substantia nigra to the striatum underlies the movement problems seen in Parkinson's disease. Dopamine itself cannot cross the blood-brain barrier, so patients are instead given levodopa, which is actively transported into the brain and converted there into dopamine. Carbidopa, an enzyme inhibitor that does not cross into the brain, is combined with levodopa to block its premature conversion in peripheral tissues, increasing the fraction that reaches the brain and reducing peripheral side effects such as nausea. This levodopa/carbidopa combination remains the foundational symptomatic treatment for Parkinson's disease and related parkinsonian disorders. With years of use, the short duration of action of standard oral levodopa produces fluctuating brain dopamine levels between doses, causing periods of symptom return ('wearing-off') and involuntary movements called dyskinesias. Extended-release oral formulations, continuous intestinal or subcutaneous infusions, and inhaled rescue formulations all aim to smooth out these fluctuations, delivering steadier drug exposure than conventional tablets. Rather than introducing a new pharmacological target, this generation of therapies re-engineers delivery of the same precursor molecule to preserve its benefit while limiting motor complications caused by uneven dosing.

By indication

Related mechanisms

dopamine precursor drugs compared

10 drugs, stage by indication
10 drugs acting on dopamine precursor: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
Crexont (IPX203)CrexontAmneal Pharmaceuticals, Knight Therapeutics, Zambon SpAsmall moleculeApprovedApproved in Parkinson's Disease
foslevodopa/foscarbidopaVyalevAbbViesmall moleculeApprovedApproved in Parkinson's Disease
Levodopa (Inbrija)InbrijaJiangxi Kvvit Pharmaceutical, Merz Therapeuticssmall moleculeApprovedApproved in Parkinson's Disease
Levodopa-carbidopa intestinal gelDuopaAbbViesmall moleculeApprovedApproved in Parkinson's Disease
ParcopaUCBsmall moleculeApprovedApproved in Parkinson's Disease
Rytary (IPX066)RytaryAmneal Pharmaceuticalssmall moleculeApprovedApproved in Parkinson's Disease
Levodopa/carbidopa (ND0612)OnerjiNeuroDerm Ltd.small moleculePhase 3Phase 3 in Parkinson's Disease
Carbidopa/levodopa (WD-1603)Hong Kong WD Pharmaceutical Co., Limitedsmall moleculePhase 2Phase 2 in Parkinson's Disease
TR-012001SNLD, Ltd.small moleculePhase 2Phase 2 in Parkinson's Disease
Melevodopa/carbidopa (Sirio)SirioChiesi Farmaceuticismall moleculePhase 1/2Phase 1/2 in Parkinson's Disease

← all mechanisms